Weiss R H, Lin P-Y
Department of Internal Medicine and Cancer Center, Division of Nephrology, University of California, Davis, California 95616, USA.
Kidney Int. 2006 Jan;69(2):224-32. doi: 10.1038/sj.ki.5000065.
Kidney cancer, although relatively rare when compared to other malignancies, occurs not uncommonly in patients with renal disease and is often discovered incidentally during the initial nephrologic work-up, or by the savvy clinician who is familiar with the paraneoplastic signs. While surgical approaches are generally curative when the disease is confined to the kidney, one-third of the cases that present in the metastatic form and require conventional medical therapy are associated with a truly dismal patient survival rate. In light of the emerging knowledge of the molecular mechanisms of kidney cancer oncogenesis, several novel and promising therapeutic approaches are emerging. In this review, we summarize the current state of kidney cancer diagnosis and therapy, as well as some of the novel treatments that capitalize on those newly elucidated molecular pathways that are deranged in this disease.
肾癌与其他恶性肿瘤相比虽相对少见,但在肾病患者中并不罕见,常于最初的肾病检查时偶然发现,或由熟悉副肿瘤综合征体征的经验丰富的临床医生发现。虽然当疾病局限于肾脏时,手术方法通常可治愈,但三分之一以转移形式出现且需要传统药物治疗的病例,患者生存率极低。鉴于对肾癌发生分子机制的新认识,一些新颖且有前景的治疗方法正在出现。在本综述中,我们总结了肾癌诊断和治疗的现状,以及一些利用该疾病中紊乱的新阐明分子途径的新疗法。